文献速递治疗药物监测与药物基因组学药物相互作用

苯妥英代谢率作为CYP2C9活性标志物优于基因型预测S-华法林清除率

Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.
PubMed 文献 · Clin Pharmacokinet · 2022-06-14

本研究在150名健康非吸烟者和60名华法林治疗患者中,评估苯妥英代谢率(PMR)预测口服S-华法林清除率(SWOCL)及CYP2C9介导代谢物形成清除率的能力。结果显示PMR与SWOCL显著相关,在多元回归模型中PMR是最强预测因子,分别解释健康者和患者中44%和38%的SWOCL变异,优于CYP2C9基因型。

要点

  • PMR与SWOCL在健康者(r=0.62/0.67)和患者(r=0.57/0.61)中均显著相关。
  • PMR是SWOCL最强预测因子,解释健康者44%、患者38%的变异。
  • PMR较CYP2C9基因型对SWOCL预测具显著优势。

核心结论

  • PMR是SWOCL的最强预测因子,优于CYP2C9基因型。

研究设计与样本

  • 研究包括150名健康非吸烟者(第1部分)和60名华法林治疗患者(第2部分)。
  • 第1部分受试者分两次接受单剂300 mg苯妥英和单剂华法林(5或10 mg)。
  • 第2部分PMR操作相同,但在华法林起始前或达稳定抗凝后执行。

主要发现

  • PMR、SWOCL和SWCLf在不同CYP2C9基因型携带者间差异显著(健康者p<0.001,患者p<0.005)。
  • PMR24/12和PMR24/24与SWOCL在健康者(r=0.62和r=0.67,p<0.001)和患者(r=0.57和r=0.61,p<0.001)中显著相关。
  • 多元回归中PMR解释健康者44%、患者38%的SWOCL变异,占总解释变异的95.7%和90.5%。

临床怎么用

  • 建议在未来CYP2C9底物(治疗窗窄)的给药算法中纳入PMR,并进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CYP2C9 is a member of the cytochrome P450 (CYP) superfamily responsible for the metabolism of 16% of drugs that undergo oxidative metabolism. The activity of CYP2C9 exhibits marked inter-individual variability, which translates into prominent differences in the pharmacokinetics of CYP2C9 substrates, some of which are characterized by a narrow therapeutic window. Genetic polymorphisms in the gene encoding for CYP2C9 account for a fraction of the variability in CYP2C9 activity. The phenytoin metabolic ratio (PMR) is a marker of CYP2C9 activity in vivo, which correlates with CYP2C9 genetic polymorphisms. OBJECTIVE: The purpose of the current study was to evaluate the ability of the PMR to predict the oral clearance of (S)-warfarin (SWOCL) and its formation clearance towards its CYP2C9-mediated metabolites (SWCLf) [i.e., 6- and 7-hydroxy-(S)-warfarin]. METHODS: The study was conducted in 150 healthy non-smoker subjects (segment 1) and 60 patients treated with warfarin (segment 2). In the first segment, the participants received on two separate occasions a single 300-mg dose of phenytoin and at least 7 days later a single dose of warfarin (5 or 10 mg). The same PMR procedure was performed in the second segment, except that it was performed either before warfarin initiation or after the patients had reached stable anticoagulation. The PMR was derived from the ratio of 5-(4-hydroxyphenyl)-5-phenyl-hydantoin content in a 24-hour urine collection to plasma phenytoin concentration 12- (PMR24/12) or 24- (PMR24/24) post-dosing. In segment 1, SWOCL was calculated from the ratio of (S)-warfarin dose to the warfarin area under the plasma concentration-time curve extrapolated to infinity and the SWCLf from the ratio of urine content of 6- and 7-hydroxy-(S)-warfarin to (S)-warfarin area under the (S)-warfarin plasma concentration-time curve until the last measured timepoint. In segment 2, estimated SWOCL was derived from the ratio of (S)-warfarin dose to the mid-interval plasma concentration of (S)-warfarin. RESULTS: The PMR, SWOCL, and SWCLf varied significantly between carriers of different CYP2C9 genotypes in both healthy subjects (p < 0.001) and patients (p < 0.005). However, PMR and SWOCL values exhibited substantial intra-genotypic variability. PMR24/12 and PMR24/24 were significantly correlated with SWOCL both in healthy subjects (r = 0.62 and r = 0.67, respectively, p < 0.001) and in patients (r = 0.57 and r = 0.61, respectively, p < 0.001). In a multiple regression model that included all variables that correlated with SWOCL, PMR was the strongest predictor, explaining 44% and 38% of the variability in SWOCL among healthy subjects and patients, respectively, and accounting for 95.7% (44%/46%) and 90.5% (38%/42%) of the total explained variability in SWOCL among healthy subjects and patients, respectively. CONCLUSIONS: The PMR is the strongest predictor of SWOCL, and as such, it exhibits a significant advantage over the CYP2C9 genotype. The inclusion of PMR in future dosing algorithms of CYP2C9 substrates characterized by a narrow therapeutic window should be encouraged and further investigated.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Shaul C, Blotnick S, Adar L, et al. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clin Pharmacokinet. 2022. PMID: 35699912. doi:10.1007/s40262-022-01141-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。